CHRONIC HEPATITIS B

This large, late-stage study is testing whether a new drug called bepirovirsen can provide a functional cure for chronic Hepatitis B. It involves 857 people who are already taking standard antiviral medication. The goal is to see if adding bepirovirsen for 24 weeks can suppress t…

This study is testing if adding two new drugs (Sintilimab and Peg-IFNα-2b) to a patient's current Hepatitis B medication can lead to a clinical cure. It involves 45 adults with stable Hepatitis B who meet specific blood test criteria. The main goal is to see if this combination c…

This large Phase 3 study is testing whether an investigational drug called bepirovirsen can provide a 'functional cure' for people with chronic Hepatitis B. It involves nearly 1,000 participants who are already on standard antiviral medication. The main goal is to see if adding b…

This study is testing whether two new injections, called HT-101 and HT-102, can help control chronic Hepatitis B. It will involve 60 patients who already have the virus to see if the treatment can reduce or eliminate detectable virus in their blood. The main goal is to find the b…

This study is testing the safety and effects of two new injections, HT-101 and HT-102, in people with chronic hepatitis B. About 86 participants will receive the injections every four weeks for up to 48 weeks, while continuing their standard antiviral pills. The main goal is to s…

This study is testing whether adding a new tablet called TQ-A3334 to standard hepatitis B medications works better than the standard medications alone. It involves 116 adults with chronic hepatitis B who are either starting treatment or already on stable treatment. The main goal …

This study is testing whether empagliflozin, a medication for diabetes, can prevent or slow the progression of liver scarring (fibrosis and cirrhosis) in people with chronic hepatitis B. The 106 participants are already taking standard antiviral drugs but still have significant l…

This study is testing whether a new injection called BW-20507, when given alongside a standard Hepatitis B drug (pegylated interferon), is safe and effective at controlling the virus. It involves 209 adults with chronic Hepatitis B who meet specific health criteria. The main goal…

This study is testing whether the drug TMF can safely control Hepatitis B virus in people who have normal liver enzyme levels. Researchers are enrolling 200 patients who have never received treatment before to see if TMF reduces virus levels and prevents liver damage. The trial c…

This large, late-stage study is testing whether a new injection called AHB-137 can help people with a specific type of chronic hepatitis B. The goal is to see if the injection can keep the virus under control even after participants stop taking their current daily antiviral pills…

This study aimed to test whether adding an experimental drug called ARC-520 to standard Hepatitis B medications could better control the virus. It was designed for adults already taking daily antiviral pills. The trial was withdrawn by the sponsor before any patients were enrolle…

This study is testing whether adding an experimental injection called AHB-137 to standard hepatitis B treatments can help patients eventually stop their daily antiviral pills. The research involves 127 adults with a specific type of chronic hepatitis B who are already taking anti…

This study tested a treatment combining the standard drug Tenofovir with four specific herbal extracts and Vitamin C for people with chronic Hepatitis B. The goal was to see if this combination could more effectively suppress and potentially clear the Hepatitis B virus from the b…

This study is for people with chronic hepatitis B who stopped their antiviral medication, then had a dangerous flare-up of the virus. It tests if switching to a newer drug called tenofovir alafenamide (TAF) is effective at getting the virus back under control and protecting the l…

This large clinical trial is testing a new medication called hepenofovir for people with chronic hepatitis B. Researchers are comparing different doses against a standard treatment to find the most effective and safest option. The goal is to better control the hepatitis B virus l…

This study is testing an experimental drug called AHB-137 in adults with chronic hepatitis B who have never received treatment. The main goal is to see if the drug can reduce the hepatitis B virus to very low or undetectable levels in the blood. Researchers will also monitor side…

This study is testing if the antiviral medicine tenofovir is safe and effective at controlling chronic hepatitis B in children aged 2 to under 12. About 90 children will be randomly assigned to receive either the real medicine or a placebo (a dummy pill) for 48 weeks. The main go…

This study is testing whether a new two-part immunotherapy called VTP-300, given with a low dose of an existing drug (nivolumab), can help the body's immune system better control chronic Hepatitis B. It involves 120 adults whose virus is already suppressed by daily pills. The mai…

This early study is testing a new injection called TVAX-008. It aims to see if it can safely boost the body's immune response in people who have chronic Hepatitis B but currently have very low levels of the virus. The study will enroll 20 adults to check if the injection increase…

This study aims to understand what happens when patients with chronic hepatitis B stop their long-term antiviral medications. Researchers will monitor 54 patients who meet specific criteria to stop treatment, tracking their immune system and virus levels. The goal is to learn why…